Comparing Ocrevus vs Tysabri
| Ocrevus (ocrelizumab) | Tysabri (natalizumab) |
|
|---|
| Ocrevus (ocrelizumab) | Tysabri (natalizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ocrevus is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate, reducing inflammation in people with MS. After an initial loading dose, it is given by IV infusion every... View more |
Prescription only
Tysabri may be used to treat adults with multiple sclerosis or Crohn's disease and is given once every four weeks through an infusion center registered with the Touch Prescribing Program. A headache... View more |
Related suggestions |
|||||||||||||||
| More about Ocrevus (ocrelizumab) | More about Tysabri (natalizumab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Ocrevus has an average rating of 5.3 out of 10 from a total of 176 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 42% reported a negative effect. |
Tysabri has an average rating of 7.7 out of 10 from a total of 98 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 15% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Ocrevus side effects |
View all Tysabri side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Ocrevus prices |
View all Tysabri prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Other natalizumab brands include: Tyruko | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
624 hours |
360 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 433 drugs are known to interact with Ocrevus:
|
A total of 414 drugs are known to interact with Tysabri:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
March 28, 2017 |
November 23, 2004 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.